The industry is fueled by the identification of new biomarkers that facilitate more accurate autoimmune diagnosis. Additionally, it is projected that the market for autoimmune disease diagnostics would expand as a result of consumers' growing preference for direct-to-consumer testing.
Organ-specific autoimmune diseases—where the autoantibodies target a single organ—and non-organ-specific autoimmune diseases—where the autoantibodies target numerous organ systems—are the two broad categories into which autoimmune diseases can be subdivided. Approximately 50 million Americans today have autoimmune-related ailments, according to the American Autoimmune Related Diseases Association. Furthermore, during the course of the projected year, the numbers are anticipated to rise.
The Global Autoimmune Disease Diagnosis Market study provides market data by the competitive landscape, revenue analysis, market segments and detailed analysis of key market players such as; Abbott Laboratories Inc., Bio-Rad Laboratories, bioMérieux SA, Danahar Corp., F. Hoffmann-La Roche AG, Labcorp Acquires Assets of Myriad Genetics, Merck and co. Acquired Pandion Therapeutics, Oncimmune Acquires Protagen Diagnostics, PerkinElmer Acquires Euroimmune, Quest Diagnostics Acquires Labtech Diagnostics, Sebia Acquires ORGENTEC Diagnostika, Siemens Healthineers, Thermo Fisher Scientific Inc.
SPER Market Research study aims to provide market dynamics, demand and supply with yearly forecast to 2030. This report provides data for growth estimates and forecasts for product type segment - By Product (Consumables And Assay Kits, Instruments), By End User (Clinical Laboratories and Hospitals), By Test Type (Routine Laboratory Tests, Autoantibodies Tests, Immunologic Tests and Other Tests).
This report also provides the data for key regional segments of North America, Europe, Asia-Pacific, Middle East & Africa.
This study also encompasses various drivers and restraining factors of this market for the forecast period. Various growth opportunities are also discussed in the report.